February 2018

Important New Products

• Trumenba (meningococcal group B vaccine) prevents meningococcal serogroup B disease ...(more)

New Indications

• Gazyva (obinutuzumab (rch)) in combination with chemotherapy followed by Gazyva ...(more)
• Xalkori (crizotinib) is now indicated for the treatment of ROS1 positive advanced ...(more)

New Contraindications

Combined oral contraceptives (COCs) including Brevinor, Brevinor-1, Norimin, Norimin-1 ...(more)
• Cervidil (dinoprostone) should not be used or left in place when other labour inducing ...(more)
• Noriday 28 (norethisterone) is now contraindicated with hepatic adenomas or carcinomas. ...(more)
• Prednefrin Forte (prednisolone acetate/phenylephrine hydrochloride) is now ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. 

To contact MIMS editorial please email editorial@mims.com.au. To enquire about purchasing a product please contact MIMS Customer service on 1800 800 629 or email subscriptions@mims.com.au. For more information about MIMS, please see www.mims.com.au

Copyright © 2018 MIMS Australia Pty Ltd. All rights reserved.
Our mailing address is:
MIMS Australia, Level 2, 1 Chandos Street, St Leonards NSW 2065, Phone: 1800 800 629